Culture media matters – why one size does not fit all

Culture media do far more than simply keep cells alive; they provide the conditions and raw materials that influence cell growth, viability, health, and metabolism. Unsuitable media can affect cell morphology, process reproducibility, and the formation of unwanted host cell proteins and by-products. These factors can impact product titers, yields, and quality, and may also influence downstream processing, scalability and, ultimately, commercial viability. Additionally, poorly matched media can introduce variability, making it difficult to distinguish genuine biological effects from problems caused by the culture environment. Culture media should therefore be treated as an important process variable that can be optimized, rather than simply as another consumable.

Why generic culture media are not always ideal

Off-the-shelf media formulations are designed to work across a wide range of applications, offering broad compatibility and convenience. However, different cell types have varying nutritional and physiological requirements, which can affect their metabolic behaviors and environmental responses. This means that formulations developed for one biological system may not deliver the same results in another. When focusing on just one cell line, a medium selected because it supports sufficient growth during early development may become unsuitable as the process evolves, or as the target molecule or manufacturing process changes. Manufacturers are also adopting more diverse cell lines and producing increasingly complex products, making it less feasible for a single 'standard' formulation to perform equally well across every application.

Cell culture media must be designed to suit the specific combination of cell line, target product, and manufacturing process, with customization taking place as early as possible before the manufacturing process becomes locked into preclinical or clinical data. It may seem counterintuitive, but aiming purely for the fastest cell growth may not produce the best overall outcome, and the best formulation does not necessarily maximize every performance metric. In reality, slower growth may be preferable if it supports better product quality and purity, lowers costs, or allows for a more scalable process.

Media can be customized to a particular platform – a defined family of cells or processes – offering standardization, speed, and operational familiarity. Bespoke media are even more specific to the requirements of one cell line, product, or process, but usually require greater resources to develop.

• Off-the-shelf media: broad compatibility and convenience, but limited alignment with the specific cell and process.
• Platform media: consistency across a defined family of cells or products; a better fit than generic media but not necessarily optimal for every application.
• Bespoke media: performance against the objectives of one process; greater development input, but more scope for targeted improvement.

The benefits of culture media customization

Tailoring cell culture media to the needs of a specific platform or cell line can improve growth, viability, and cellular health while reducing stress. These improvements can increase product titers and yields, shorten production cycles, and enhance product quality. Defined formulations also limit the presence of unwanted metabolic by-products and host cell proteins. In addition, typical media contains undefined or animal-derived components – such as fetal bovine serum (FBS) and human platelet lysate (HPL) – which are prone to variability, safety concerns, and supply chain issues. This can complicate regulatory approvals, potentially delaying accessibility to critical treatments such as cell and gene therapies.

From a commercial point of view, customizing cell culture media gives manufacturers more control over their processes and helps them to balance biological performance against raw material costs. For instance, it may be possible to remove or replace expensive or difficult-to-source ingredients to improve supply chain resilience and reduce dependence on individual suppliers. Defined, customized cell culture formulations often reduce the total volume of medium needed for greater cost and resource efficiency. They are also easier to troubleshoot if there are process issues compared with media containing undefined or animal-derived components, and can simplify downstream purification.

Using AI to streamline optimization

The optimum cellular environment depends on the complete formulation, not individual ingredients in isolation, making finding the optimal combination extremely laborious. Manual trial-and-error methods cannot efficiently explore all the possible combinations and concentrations within complex media, which can contain over 100 different components.

AI algorithms can make systematic media optimization more manageable and reduce development times. MediOP™ integrates cell biology expertise, high-throughput robotic automation, analytics, and AI to identify bespoke formulations. Scientists first define the objectives and constraints for a specific cell line – such as growth, viability, morphology, product titer, and cost – before automated systems prepare and test formulations, and measure the resulting biological and process outputs. Active learning models based on Bayesian optimization then use this data to identify relationships between media composition and cell performance to select formulations for the next round of experiments. Repeating this cycle quickly narrows the search toward a formulation that balances the selected criteria. This empirical approach can explore complex ingredient interactions without requiring every underlying biological mechanism to be fully understood, making bespoke media development more achievable.

Example – CHO cells

CHO cells are the principal production system for monoclonal antibody manufacturing. Decades of incremental development have produced effective CHO platform media, and generic, chemically defined formulations free from protein and FBS are routinely used in CHO workflows. These well-established platform media can provide a sufficient starting point, but customization dramatically improves factors such as monoclonal antibody titers, metabolic by-product profiles, and host cell protein profiles. Tailoring a medium to a cell line also reduces media costs and streamlines downstream purification, benefiting the entire workflow from start to finish.

For example, we used our AI-driven MediOP™ platform to screen 150 de novo CHO DG44 feed formulations over the course of two months. The final bespoke formulation doubled monoclonal antibody expression, and reduced media costs by 50-60 percent. This demonstrated a scalable CHO media optimization process that could be applied in both early-stage development and commercial media design.

Example – stem cells

Most stem cell therapies – such as donor-derived mesenchymal stem cells (MSCs) intended for osteoarthritis and rheumatoid arthritis therapies – are still expanded in HPL, which introduces lot-to-lot variability, dependence on donated material, and regulatory scrutiny. Chemically defined media can improve safety and batch consistency, but must preserve the cell morphology and biological characteristics that are crucial for function, rather than merely maximizing proliferation.

We used MediOP^™ to develop Proliferum-UC, a chemically defined medium for human umbilical cord-derived MSCs (UC-MSCs), that is free from human- or animal-derived components. By placing tight biological constraints on the design space, our scientists maximized cell growth without compromising key functional properties, such as differentiation capacity. This was achieved with only three months of development time. UC-MSCs grown in Proliferum-UC retain trilineage differentiation into bone, cartilage, and fat, and expand at rates close to those achieved in HPL-supplemented media. They also show 60 percent higher indoleamine 2,3-dioxygenase (IDO) activity – a key marker of immunomodulatory function – than cells grown in a leading commercial chemically defined medium.

Proliferum® P is the first commercially available, animal component-free (ACF) media formulation specifically developed for porcine adipose-derived stem cells. Proliferum® P was developed in under six months using MediOP^™ and demonstrates performance that matches or exceeds that of FBS. Crucially, it preserves critical stem cell characteristics and differentiation capacity, offering a cost-effective, scalable, and reliable alternative to traditional formulation methods.

Matching media to each application

Culture media can influence cell performance, product quality, and manufacturing efficiency, but no single formulation can meet the needs of every application. Customization allows manufacturers to balance biological performance with consistency, scalability, regulatory requirements, and costs. Data-driven media optimization can improve established processes and help to meet the need of applications where suitable media solutions remain limited.

Multus Biotechnology combines automated experimentation, high-throughput analytics, and data-driven optimization to identify suitable existing media, refine baseline formulations, and develop bespoke media tailored to specific cell lines, products, and processes. Get in touch with the Multus team to discuss how multi-objective media optimization could help balance growth, function, product quality, and cost for your application.